Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22952600 | 0.87 | KDM4E (0.34) | ALDH1A1 | |
| SCHEMBL22952607 | 0.87 | KDM4E (0.34) | ALDH1A1 | |
| SCHEMBL29440460 | 0.87 | KDM4E (0.34) | ALDH1A1 | |
| SCHEMBL28936693 | 0.87 | KDM4E (0.34) | ALDH1A1 | |
| SCHEMBL28711060 | 0.87 | KDM4E (0.34) | ALDH1A1 | |
| SCHEMBL28936695 | 0.87 | KDM4E (0.34) | ALDH1A1 | |
| SCHEMBL29440439 | 0.87 | KDM4E (0.34) | ALDH1A1 | |
| SCHEMBL4927218 | 0.84 | AOC3 (0.43) | AOC3CHRM2CHRM1CHRM3CASR | |
| SCHEMBL20422038 | 0.84 | SMN1; SMN2 (0.34) | ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL21507531 | 0.84 | ATM (0.36) | AOC3ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220125-A1 | FUSED ISOINDOLIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-14 | — | — | US | disclosed |
| WO-2020212434-A1 | FUSED ISOINDOLIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220125-A1 | FUSED ISOINDOLIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS | GRK2, GRK1, GRK3 | AOC3 4220/4885CHRM2 2557/4885CHRM1 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.